Cited by 624Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Paz-Ares, Luis G., de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare·2013·Journal of Clinical Oncology

DOI 10.1200/jco.2012.47.1102

Open this paper in CoChat — free account

Abstract

PURPOSE: In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data. PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). Log-rank test compared OS between arms as measured from random assignment (α = .0498). RESULTS: The mean number of maintenance cycles was 7.9 (range, one to 44) for pemetrexed and 5.0 (range, one to 38) for placebo. After 397 deaths (pemetrexed, 71%; placebo, 78%) and a median follow-up of 24.3 months for alive patients (95% CI, 23.2 to 25.1 months), pemetrexed therapy resulted in a statistically significant 22% reduction in the risk of death (HR, 0.78; 95% CI, 0.64 to 0.96; P = .0195; median OS: pemetrexed, 13.9 months; placebo, 11.0 months). Survival on pemetrexed was consistently improved for all patient subgroups, including induction response: complete/partial responders (n = 234) OS HR, 0.81; 95% CI, 0.59 to 1.11 and stable disease (n = 285) OS HR, 0.76; 95% CI, 0.57 to 1.01). Postdiscontinuation therapy use was similar: pemetrexed, 64%; placebo, 72%. No new safety findings emerged. Drug-related grade 3 to 4 anemia, fatigue, and neutropenia were significantly higher in pemetrexed-treated patients. CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.47.1102

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
AJCC Cancer Staging Manual
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 6,011
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Self-citation

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 1

Ciuleanu T, 2008, Ann Oncol, 19, viii98

Sorted by citations

Items 401–500 of 622

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
Yang, J. C., Ahn, M., Nakagawa, K., Tamura, T., Barraclough, H., Enatsu, S., Cheng, R., & Orlando, M. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2013.266 · Cited by 4
Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
Pietanza, M. C., Hellmann, M. D., Fiore, J. J., Smith–Marrone, S., Basch, E., Schwartz, L. H., Ginsberg, M. S., Shouery, M., Newman, S. K., Shaw, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.018 · Cited by 4
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Pacheco, J. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.03 · Cited by 4
The changing landscape of stage III lung cancer: a literature review
Patel, M., Bruno, D. S., Grubb, W., & Biswas, T. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1796645 · Cited by 4
Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells
Ko, J., Chen, J., Tseng, P.-Y., Hsieh, J.-M., Chiang, C.-S., Liu, L., Chien, C.-C., Huang, I.-H., & Lin, Y. (2022) · Toxicology Research · doi:10.1093/toxres/tfac013 · Cited by 4
Long Progression-free Survival by Pemetrexed Continuation Maintenance Therapy Following Cisplatin-based Chemotherapy in Malignant Pleural Mesothelioma
Takeda, T., Itano, H., Fukita, S., Saitoh, M., & Takeda, S. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.2094 · Cited by 4
Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective
Horinouchi, H. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw131 · Cited by 4
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
Nishimoto, K., Karayama, M., Inui, N., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1172-x · Cited by 4
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
Park, J. H., Kwon, B. S., Park, S. J., Ji, W., Yoon, S., Choi, C., & Lee, J. C. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02941-z · Cited by 4
Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis
Liu, N., Zhang, B., He, J., & Su, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635757 · Cited by 4
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
Rathbone, M., O’Hagan, C., Wong, H. H., Khan, A. M., Cook, T., Rose, S., Heseltine, J., & Escriu, C. (2024) · Cancers · doi:10.3390/cancers16071249 · Cited by 3
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study
Shima, Y., Yoshida, H., Suminaga, K., Yoshida, H., Hashimoto, K., Ogimoto, T., Hosoya, K., Ajimizu, H., Funazo, T. Y., Nomizo, T., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13785-x · Cited by 3
Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study
Kamath, M. P., Lakshmaiah, K., Babu, K. G., Loknatha, D., Jacob, L. A., & Babu, S. (2016) · Lung India · doi:10.4103/0970-2113.177448 · Cited by 3
Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer
Igawa, S., Otani, S., Nakahara, Y., Ryuge, S., Hiyoshi, Y., Fukui, T., Mitsufuji, H., Kubota, M., Katagiri, M., Sato, Y., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0472-x · Cited by 3
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours
Chen, Y., Hong, Y., Fu, Y., Li, Q., Lin, P., & Ding, Z. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.8.2415 · Cited by 3
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience
Faber, M. G., Wang, C., Reddy, S. K., Meagher, A. K., Early, A., Chen, H., & Dy, G. K. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.010 · Cited by 3
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens
Marrett, E., Kwong, W. J., Xie, J., Manceur, A. M., Sendhil, S. R., Wu, E. Q., Ionescu‐Ittu, R., & Subramanian, J. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00383-1 · Cited by 3
Systematic analysis of apoptosis-related genes in the prognosis of lung squamous cell carcinoma: a combined single-cell RNA sequencing study
Zhu, P., Yang, W., Wang, B., Zeng, T., Hu, Z., Zhang, D., Yang, Z., Wang, K., & Pu, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1712 · Cited by 3
Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer
Koba, T., Minami, S., Nishijima-Futami, Y., Masuhiro, K., Kimura, H., Futami, S., Yaga, M., Mori, M., Kagawa, H., Uenami, T., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3598-4 · Cited by 3
Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities
Fountzilas, E., Levva, S., Mountzios, G., Polychronidou, G., Maniadakis, N., Kotoula, V., & Fountzilas, G. (2018) · Journal of Global Oncology · doi:10.1200/jgo.18.00115 · Cited by 3
Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
Patel, S. A., Gerber, D. E., Deal, A. M., Douglas, K., Pecot, C. V., Lee, C. B., Schiller, J. H., Dhruva, N., & Weiss, J. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666691 · Cited by 3
Feasibility Re-evaluation of 75 mg/m2 Docetaxel in Japanese Patients with Previously Treated Non-small Cell Lung Cancer
Yamada, K., Takeoka, H., Mizoguchi, Y., Yamashita, F., Yoshida, T., Zaizen, Y., Okayama, Y., Naito, Y., Azuma, K., & Hoshino, T. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt236 · Cited by 3
Thymic malignancies: Moving forward with new systemic treatments
Remón, J., Lindsay, C. R., Bluthgen, M. V., & Besse, B. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.013 · Cited by 3
Impact des traitements utilisés en oncologie thoracique sur la fonction rénale
Toffart, A., Belaiche, S., Moro‐Sibilot, D., Couraud, S., & Sakhri, L. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.03.008 · Cited by 3
Contexto actual de los inhibidores de EGFR/ErbB en carcinoma de pulmón no microcítico
Álvarez-Fernández, C., & Esteban, E. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(16)30256-1 · Cited by 3
Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study
Chen, L., Antonio, B. S., Yan, Y., Chen, J., Goodloe, R., & John, W. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1297700 · Cited by 3
Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer
Shen, L., Niu, X., Jian, H., Xu, Y., Yu, Y., & Lü, S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.001 · Cited by 3
Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial
Zhang, L., Belani, C. P., Zhang, P.-H., Wang, X., Yang, L., Orlando, M., & Wu, Y.-L. L. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.026 · Cited by 3
Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów
Jassem, J., Biernat, W., Bryl, M., Chorostowska‐Wynimko, J., Dziadziuszko, R., Krawczyk, P. A., Kordek, R., Kowalski, D. M., Krzakowski, M. J., Olszewski, W. T., et al. (2014) · Advances in respiratory medicine · doi:10.5603/piap.2014.0019 · Cited by 3
New Options on the Horizon for Nononcogene Addicted Non-Small-Cell Lung Cancer
Paglialunga, L., Ricciardi, S., & D’Arcangelo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0096 · Cited by 3
Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer
Uprety, D. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.006 · Cited by 3
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma
Akiyama, N., Karayama, M., Inui, N., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00747-x · Cited by 3
Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
Russo, A., Scilla, K. A., & Rolfo, C. D. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.06.24 · Cited by 4
Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
Joung, E. K., Yang, J. H., Oh, S., Park, S. J., & Lee, J. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.129 · Cited by 3
Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study
Umehara, K., Yama, K., Koike, N., Takayama, S., Wakamoto, A., Hatuyama, T., Kobayashi, M., & Sato, H. (2020) · Renal Replacement Therapy · doi:10.1186/s41100-020-00292-x · Cited by 3
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer
The Singapore Cancer Network (SCAN) Lung Cancer Workgroup (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n10p449 · Cited by 3
Lung Cancer: Diagnosis and Treatment Approach
Tantraworasin, A., Suksomboonchroen, T., Wannasopha, Y., Kongkarnka, S., Saeteng, S., Lertprasertsuke, N., Euathrongchit, J., & Chewaskulyong, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-21683-6_7 · Cited by 3
Molecular Characterization May Be of PARAMOUNT Importance
Dearing, K. R., & Weiss, G. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3893 · Cited by 3
What is Currently the Best for Adenocarcinoma without Driver Mutation?
Park, C., Oh, I., & Kim, Y. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0024 · Cited by 3
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Cummings, A. L., & Garon, E. B. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.07.06 · Cited by 2
Long-term responders to palliative chemotherapy for advanced biliary tract cancer.
Doherty, M. K., McNamara, M. G., Aneja, P., Horgan, A. M., Jang, R. W.-J., Dhani, N. C., Hedley, D. W., & Knox, J. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.391 · Cited by 3
Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non–Small Cell Lung Cancer in Jordan
Rabayah, A. A., Froukh, R. F. A., Sawalha, R. D., Shnekat, M. A., Jahn, B., Siebert, U., & Jaddoua, S. M. (2024) · Value in Health Regional Issues · doi:10.1016/j.vhri.2024.101004 · Cited by 2
Efficacy and Safety of Ivonescimab in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): A Systematic Review
Matairi, A. A., Hammadeh, B. M., Aldalati, A. Y., Qtaishat, F. A., Nashwan, A. J., & Alzibdeh, A. M. (2025) · Cureus · doi:10.7759/cureus.77381 · Cited by 3
Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study
Japelj, N., Horvat, N., Jazbar, J., Kerec Kos, M., Pelicon, V., & Knez, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1682723 · Cited by 2
Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report
Watanabe, H., Tamura, T., Kagohashi, K., Kawaguchi, M., Kurishima, K., & Satoh, H. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.756 · Cited by 2
Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer
Karayama, M., Inui, N., Kusagaya, H., Suzuki, S., Inoue, Y., Enomoto, N., Fujisawa, T., Nakamura, Y., & Suda, T. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3017-7 · Cited by 2
The Use of Systemic Treatment in the Maintenance of Patients with Non-small Cell Lung Cancer
Kulkarni, S., Vella, E. T., Coakley, N., Cheng, S., & Gregg, R. W. (2015) · Cited by 2
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
Jia, B., Dong, Z., Wu, D., Zhao, J., Wu, M., An, T., Wang, Y., Zhuo, M., Li, J., Wang, Y., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01662-5 · Cited by 2
Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Eisner, J. R., Mayhew, G. M., Davison, J. M., Beebe, K. D., Shibata, Y., Guo, Y., Farhangfar, C. J., Farhangfar, F., Uronis, J. M., Conroy, J. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2558 · Cited by 2
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Katakami, N., Nishimura, T., Hidaka, Y., Hata, A., Nishino, K., Mori, M., Hirashima, T., Takase, N., Kaneda, T., Ohnishi, H., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107261 · Cited by 2
Prognostic significance of PNI, SIRI and LIPI in non small-cell lung cancer
Balçık, O. Y., AYTAÇ, A., Avcı, T., Demir, B., İlhan, Y., Karakaya, G., & Erdoğan, A. P. (2023) · Acta Medica Alanya · doi:10.30565/medalanya.1314292 · Cited by 2
Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia
Roig, M., Colomé, D. C., Colomer, G. B., Sardo, E., Tournour, M. A., Fernandez, S., Ominetti, A. I., Juvanteny, E. P., Josep Lluis Molinero, P. O. L. O., Jobal, D. B., et al. (2024) · Current Oncology · doi:10.3390/curroncol31040159 · Cited by 3
Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy
Foureau, A. V. I., Foureau, D., McHale, C. C., Guo, F., Farhangfar, C. J., & Mileham, K. F. (2024) · Cancers · doi:10.3390/cancers16132475 · Cited by 2
A strong association between TTF-1 expression and interstitial lung disease in predicting the efficacy of PD-1 inhibitor for nonsquamous NSCLC patients
Ito, M., Honda, T., Onishi, I., Endo, S., Mochizuki, A., Nishiyama, N., Sakakibara, R., Takahashi, S., Kumagai, T., Hata, K., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00628-2024 · Cited by 2
Evaluation of the efficacy of PD‑1/PD‑L1 inhibitor plus bevacizumab and chemotherapy for the treatment of patients with driver gene‑negative advanced‑stage lung adenocarcinoma: A retrospective cohort study
Yang, X., Li, X., Huang, K., & Zhuang, X. (2024) · Oncology Letters · doi:10.3892/ol.2024.14799 · Cited by 2
Managing Bone Metastases with Denosumab: Real-World Data and Critical Monitoring Points in Breast, Lung, and Prostate Cancers
Orhan, S. O., Orhan, B., ESENBUĞA, Ş., Sali, S., Caner, B., Ocak, B., Şahin, A. B., Deligönül, A., Evrensel, T., & Çubukçu, E. (2025) · Medicina · doi:10.3390/medicina61091637 · Cited by 2
Do we Need Maintenance Chemotherapy in Advanced NSCLC in the Era of Immune and Targeted Therapy?
Nagy, A. M., Rahman, O. A., Abdullah, H., & Negida, A. (2018) · Current Cancer Therapy Reviews · doi:10.2174/1573394714666180417160205 · Cited by 2
First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China
Chang, Q., Zhang, Y., Xu, J., Zhong, R., Qiang, H., Zhang, B., Han, B., Qian, J., & Chu, T. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13025 · Cited by 2
Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Lavaud, P., Besse, B., de Baère, T., Deschamps, F., Mussot, S., Pechoux, C. L., Caramella, C., Mercier, O. M., Mezquitta, L., Botticella, A., et al. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02222-9 · Cited by 2
Costs of Extended Use of the Immune Check Point Inhibitors in 1st-line Non-Small Cell Lung Cancer
Guirgis, H. M. (2021) · Journal of Clinical and Medical Research · doi:10.37191/mapsci-2582-4333-3(5)-086 · Cited by 2
Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer
Takiguchi, Y., Iwasawa, S., Minato, K., Miura, Y., Gemma, A., Noro, R., Yoshimori, K., Shingyoji, M., Hino, M., Ando, M., et al. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0755-6 · Cited by 2
Maladie oligométastatique dans le cancer bronchique non à petites cellules
Quoix, É., Milleron, B. J., & Beau‐Faller, M. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70605-6 · Cited by 2
Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective
Girard, N. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.845093 · Cited by 2
Pemetrexed as indispensable drug for the treatment of non-squamous non-small cell lung cancer; the role in induction and maintenance therapy
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.157 · Cited by 2
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
Lu, S.-L., Hsu, F., Chen, K., Ho, C., Yang, J. C., & Cheng, J. C. (2016) · Case Reports in Oncology · doi:10.1159/000448804 · Cited by 2
Changing health care costs for NSCLC, what does it mean?
Postmus, P. E. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.006 · Cited by 2
Immunotherapy and Lung Cancer
Gandhi, L., Vansteenkiste, J., & Shepherd, F. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00050-0 · Cited by 2
Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
Patil, V., Joshi, A., Noronha, V., Agarwala, V., Chougule, A., Kannan, S., Bhattacharjee, A., Chandrasekharan, A., Pande, N., Simha, V., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27214 · Cited by 2
Doublet vs Single-Agent Maintenance Therapy in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis
Qi, J., Guo, X., & Li, A. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s161542 · Cited by 2
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Guo, L., Zhang, M., Zhang, H., Zhou, J., Cai, X., Yu, L., Guo, Q., Yang, N., Zhao, J., Xie, Z., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01568 · Cited by 2
Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI
Chen, H., Shen, J., Lin, Y. N., Du, W., Zhou, J., & Li, Q. Y. (2021) · Medicine · doi:10.1097/md.0000000000024688 · Cited by 2
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients
Nakamura, R., Yamada, T., Morimoto, K., Nakao, A., Gotô, Y., Ogura, Y., Takeda, T., Takumi, C., Onoi, K., Chihara, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03866-2 · Cited by 2
Maintenance therapy for long-term control of high-grade endometrial stromal sarcoma
Nakanishi, K., Maeoka, Y., Yamada, T., & Suzuki, S. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-248971 · Cited by 2
Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers
Yuan, G., Wang, L., Li, J., Feng, H., Ji, J., Gu, W., & Shan, B. (2019) · Clinical Cancer Drugs · doi:10.2174/2212697x06666191021125423 · Cited by 2
Twenty‐five years of Respirology: Advances in lung cancer
Ang, M., & Mok, T. S. K. (2019) · Respirology · doi:10.1111/resp.13745 · Cited by 2
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease
Rangachari, D., & Costa, D. B. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.02.28 · Cited by 2
A long‐term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non‐squamous non‐small cell lung cancer
Furugen, M., Shibahara, D., Kiyuna, T., Kami, W., Miyagi, K., Haranaga, S., Kubota, T., Matsumoto, H., Yoshimi, N., & Fujita, J. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3650 · Cited by 2
PARAMOUNT Trial: Reopening a Window to Maintenance Therapy
Barni, S., & Petrelli, F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9875 · Cited by 2
Is It Time for Maintenance Chemotherapy for Advanced Gastric Adenocarcinoma?
Eren, O. Ö., Sönmez, Ö., & Oyan, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8088 · Cited by 2
A new era of treating advanced lung cancer is upon us
Weiss, G. J. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.03 · Cited by 2
Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice
Addeo, A., Banna, G. L., & Friedlaender, A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.024 · Cited by 2
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Sun, L., Xiong, Z., & Han, C. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.02.07 · Cited by 1
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%
Olivares-Hernández, A., Posado-Domínguez, L., Redondo-González, J. C., Corvo-Félix, L., Hernández, L. B., Fonseca‐Sánchez, E., & del Barco, E. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-513 · Cited by 1
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016
Gelsomino, F., Boni, L., Tiseo, M., Ricciardi, S., Rocco, D., Cortinovis, D. L., Proietto, M., Cogoni, A. A., Pasello, G., Camerini, A., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108059 · Cited by 1
Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial
Disher, N. G., Dieckmann, N. F., Case, J., Rubim, F., Eden, K., Golden, S. E., Matlock, D. D., Coleman, C. A., Lyons, K. S., Saha, S., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2475733 · Cited by 1
Immune Checkpoint Inhibitor Without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
Gao, M., Nie, Y., Wang, T., Jing, F., Zhang, F., Tao, H., Ma, J., Wang, L., & Hu, Y. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.08.011 · Cited by 1
Pseudocellulitis in a patient with non-small cell lung cancer on carboplatin, pemetrexed and pembrolizumab
Beadman, T., & Chan, M. M. K. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-269581 · Cited by 1
Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
Kim, D. H., Kinmond, A., Gilani, S., Giridharan, S., & Jegannathen, A. (2015) · Forum of Clinical Oncology · doi:10.1515/fco-2015-0008 · Cited by 1
Place des traitements d’entretien et de la pause thérapeutique complète dans la prise en charge des cancers colorectaux métastatiques non résécables
Senellart, H., Hiret, S., Guerin‐Meyer, V., & Bennouna, J. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1984 · Cited by 1
Pemetrexed in Non-Small-Cell Lung Cancer
Dediu, M., Alexandru, A., & Bratu, F. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.16 · Cited by 1
Maintenance therapy in NSCLC
Brodowicz, T. (2012) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-012-0062-8 · Cited by 1
Dose erlotinib add beneficial effect on cytotoxic agent for patients with pretreated advanced non-small cell lung cancer?
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.57 · Cited by 1
Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients
Min, Y. J. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.87.5.537 · Cited by 1
Ewolucja systemowego leczenia przeciwnowotworowego
Krzakowski, M. J. (2015) · Nowotwory Journal of Oncology · doi:10.5603/njo.2015.0001 · Cited by 1
Long Progression-Free Survival With Afatinib In A Patient With Heavily Pretreated Lung Adenocarcinoma Without Common Activating EGFR Mutations
Serra-Solé, Ò., Pujol-Riqué, M., & Cuartero, L. C. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.20 · Cited by 1
Maintenance Chemotherapy for Advanced Non-small Cell Lung Cancer
Nishio, M. (2014) · Haigan · doi:10.2482/haigan.54.887 · Cited by 1
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
Usui, N., Kondo, Y., Ryota, N., Suzuki, H., Okamoto, N., Sando, M., Tani, E., Hamaguchi, M., Tanaka, A., Tamiya, M., et al. (2016) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2016-000957 · Cited by 1
Behandlung des nichtkleinzelligen Lungenkarzinoms
Heigener, D. F., Schiller, J., & Reck, M. (2018) · Der Onkologe · doi:10.1007/s00761-018-0457-1 · Cited by 1
Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC
Rittmeyer, A. (2018) · Der Onkologe · doi:10.1007/s00761-018-0474-0 · Cited by 1
Lung Cancer
Jalal, S. I., Mamdani, H. M., Turchi, A. M., & Turchi, J. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00063-3 · Cited by 1

PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba7507 · Cited by 19
PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Reck, M., Paz-Ares, L. G., de Marinis, F., Molinier, O., Sahoo, T. P., Laack, E., John, W. J., Zimmermann, A. H., Visseren‐Grul, C., & Gridelli, C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000076 · Cited by 16
Littérature commentée décembre 2014
(2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.10.002
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Pujol, J.-L., Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Bidoli, P., Corral, J., Antonio, B. S., Chouaki, N., John, W. J., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.007 · Cited by 39
PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).
Paz-Ares, L. G., Marinis, F. D., Dediu, M., Thomas, M., Pujol, J., Bidoli, P., Molinier, O., Sahoo, T.-P., Laack, E., Reck, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra7510 · Cited by 19

See all

Authors: Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C., & Gridelli, C.
Affiliations: Heidelberg University (DE)
Luis Paz-Ares and Jesús Corral, University Hospital Virgen del Rocío, Seville, Spain; Filippo de Marinis, San Camillo-Forlanini Hospital, Rome; Paolo Bidoli, S. Gerardo Hospital, Monza; Cesare Gridelli, San Giuseppe Moscati Hospital, Avellino, Italy; Mircea Dediu, Institute of Oncology Bucharest, Bucharest, Romania; Michael Thomas, University of Heidelberg, Heidelberg; Eckart Laack, University Medical Center Hamburg-Eppendorf, Hamburg; Martin Reck, Hospital Grosshansdorf, Grosshansdorf, Germany; Jean...
ORCID: Paz-Ares, Luis G.
Dediu, Mircea
Thomas, Michael
Pujol, Jean-Louis
Molinier, Olivier
Reck, Martin
Gridelli, Cesare
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2013-08-10
Volume: 31
Issue: 23
Pages: 2895-2902
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2012.47.1102
OpenAlex: W2167191456
Cited by: 624
References: 32
Citations by year: 2026: 10 · 2025: 18 · 2024: 23 · 2023: 24 · 2022: 31 · 2021: 47 · 2020: 52 · 2019: 53 · 2018: 72 · 2017: 63 · 2016: 66 · 2015: 76 · 2014: 72 · 2013: 13
FWCI: 61.17
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Funders: Eli Lilly and Company
American Society of Clinical Oncology
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: maintenance therapy, pemetrexed, cisplatin, advanced nonsquamous non-small cell lung cancer, overall survival, induction chemotherapy, treatment safety, subgroup analysis, disease progression, prognostic factors, prognostic score, treatment-related adverse events, neutropenia, febrile neutropenia, thrombocytopenia
MeSH terms: Pemetrexed, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Double-Blind Method, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Remission Induction, Survival Analysis, Treatment Outcome, Disease-Free Survival, Induction Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks